The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
Open Access
- 1 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Parkinson's Disease
- Vol. 7 (1), 1-6
- https://doi.org/10.1038/s41531-021-00162-1
Abstract
The Trial of Parkinson’s And Zoledronic acid (TOPAZ, https://clinicaltrials.gov/ct2/show/NCT03924414) is a unique collaboration between experts in movement disorders and osteoporosis to test the efficacy of zoledronic acid, an FDA-approved parenteral treatment for osteoporosis, for fracture prevention in people with neurodegenerative parkinsonism. Aiming to enroll 3,500 participants age 65 years or older, TOPAZ is one of the largest randomized, placebo-controlled clinical trials ever attempted in parkinsonism. The feasibility of TOPAZ is enhanced by its design as a U.S.- wide home-based trial without geographical limits. Participants receive information from multiple sources, including specialty practices, support groups and websites. Conducting TOPAZ in participants’ homes takes advantage of online consent technology, the capacity to confirm diagnosis using telemedicine and the availability of research nursing to provide screening and parenteral therapy in homes. Home-based clinical research may provide an efficient, convenient, less expensive method that opens participation in clinical trials to almost anyone with parkinsonism.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (1R01AG059417-01A1)
This publication has 27 references indexed in Scilit:
- Interactive Informed Consent: Randomized Comparison with Paper ConsentsPLOS ONE, 2013
- Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotelyParkinsonism & Related Disorders, 2012
- Increasing access to specialty care: A pilot, randomized controlled trial of telemedicine for Parkinson's diseaseMovement Disorders, 2010
- The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 2009
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureThe New England Journal of Medicine, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective studyJournal of Neurology, Neurosurgery & Psychiatry, 2006
- III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal OsteoporosisEndocrine Reviews, 2002
- Interactive video conferencing: A means of providing interim care to parkinson's disease patientsMovement Disorders, 1993
- ParkinsonismNeurology, 1967